daratumumab,Talquetamab,Teclistamab,Pomalidomide
janssen,genmab,bms
nct04108195: phase 1b - subcutaneous dara with bispecific t cell redirection antibodies - trimm-2 #mmsm #multiplemyeloma #ims2022 
Multiple Myeloma Education Platform for Myeloma Community